The FDA on May 15, 2019 approved VENCLEXTA® for adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). VENCLEXTA® is a product of AbbVie Inc. and Genentech Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement